Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
ViroPharma Inc Reaffirms FY 2013 Net Product Sales Guidance
ViroPharma Inc updated its fiscal 2013 guidance and expects worldwide net product sales to be in the range of $450 to $475 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $462 million for fiscal 2013.
Latest Developments for ViroPharma Inc
- ViroPharma Inc Receives Orphan Drug Designation For Maribavir In Europe
- ViroPharma Inc Lowers FY 2013 Worldwide Net Product Sales Guidance
- ViroPharma Inc Announces Publication Of Data Demonstrating Use Of Cinryze
- ViroPharma Inc Issues FY 2013 Net Product Sales Guidance In Line With Analysts' Estimates
Latest Key Developments in Biotechnology
- Vanda Pharmaceuticals Inc Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
- CytoDyn Inc Appoints Anthony D. Caracciolo as Chairman
- Repros Therapeutics Inc Proposed Public Offering of Common Stock
- Array Biopharma Inc Announces Positive Interim Results From Combination Trial Of Arry-520 With Kyprolis At The 2013 European Hematology Association Congress
- Share this
- Link this
- Digg this
Follow Reuters